dexmethylphenidate hydrochloride

FDA Drug Profile — Dexmethylphenidate Hydrochloride Extended-Release, DEXMETHYLPHENIDATE HYDROCHLORIDE, Focalin, Dexmethylphenidate Hydrochloride, Focalin XR

Drug Details

Generic Name
dexmethylphenidate hydrochloride
Brand Names
Dexmethylphenidate Hydrochloride Extended-Release, DEXMETHYLPHENIDATE HYDROCHLORIDE, Focalin, Dexmethylphenidate Hydrochloride, Focalin XR
Application Number
ANDA210279
Sponsor
Lannett Company, Inc.
NDC Codes
50
Dosage Forms
CAPSULE, EXTENDED RELEASE, TABLET, POWDER
Routes
ORAL
Active Ingredients
DEXMETHYLPHENIDATE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14 )]. Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7) , Use in Specific Populations (8.4) ] . Dexmethylphenidate hydrochloride extended-release capsules are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ( 1 ). Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).